{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:17:04Z","timestamp":1783163824172,"version":"3.54.6"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40261-026-01554-y","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:16:29Z","timestamp":1778076989000},"page":"783-793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Nirmatrelvir\/Ritonavir after Multiple Administration in a Phase 1, Open-Label Study in Healthy Chinese Adults and Compared with Non-Chinese Participants"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct05339334","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nanyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Gerhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangchen","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1554_CR1","unstructured":"World Health Organization. Coronavirus disease (COVID-19) Epidemiological Updates and Monthly Operational Updates. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed 14 Mar 2025."},{"key":"1554_CR2","unstructured":"Paxlovid\u2122 (nirmatrelvir tablets; ritonavir tablets) [package insert]. New York, NY, USA: Pfizer Inc, 2025."},{"issue":"6575","key":"1554_CR3","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586\u201393.","journal-title":"Science"},{"issue":"1","key":"1554_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40262-023-01339-y","volume":"63","author":"J Gerhart","year":"2024","unstructured":"Gerhart J, Cox DS, Singh RSP, et al. A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of nirmatrelvir\/ritonavir. Clin Pharmacokinet. 2024;63(1):27\u201342.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1554_CR5","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1111\/bcp.15788","volume":"89","author":"DS Cox","year":"2023","unstructured":"Cox DS, Van Eyck L, Pawlak S, et al. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir\/ritonavir in healthy adults. Br J Clin Pharmacol. 2023;89(9):2867\u201376.","journal-title":"Br J Clin Pharmacol"},{"key":"1554_CR6","unstructured":"PAXLOVID (nirmatrelvir + ritonavir). Summary of Product Characteristics, Pfizer Europe, Brussels, Belgium, 2022."},{"key":"1554_CR7","unstructured":"PAXLOVID (nirmatrelvir\/ritonavir) [package insert]. Shanghai, China: Pfizer China, 2025"},{"key":"1554_CR8","unstructured":"Clinical Trials.gov. A study to learn about the study medicine PF-07321332 and ritonavir in adult healthy Chinese participants. https:\/\/clinicaltrials.gov\/study\/NCT05339334. Accessed 14 Mar 2025."},{"key":"1554_CR9","unstructured":"National Kidney Foundation. CKD-EPI creatinine equation (2021). https:\/\/www.kidney.org\/ckd-epi-creatinine-equation-2021. Accessed 20 Mar 2025."},{"key":"1554_CR10","unstructured":"US Department of Health and Human Services. Bioanalytical method validation: guidance for industry. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 5 Sept 2025."},{"key":"1554_CR11","unstructured":"European Medicines Agency. Guideline on Bioanalytical Method Validation. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 19 Jan 2022."},{"issue":"12","key":"1554_CR12","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/psp4.13039","volume":"12","author":"PLS Chan","year":"2023","unstructured":"Chan PLS, Singh RSP, Cox DS, et al. Dosing recommendation of nirmatrelvir\/ritonavir using an integrated population pharmacokinetic analysis. CPT Pharmacomet Syst Pharmacol. 2023;12(12):1897\u2013910.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"15","key":"1554_CR13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397\u2013408.","journal-title":"N Engl J Med"},{"issue":"2","key":"1554_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jcph.2353","volume":"64","author":"RSP Singh","year":"2024","unstructured":"Singh RSP, LaBadie RR, Toussi SS, et al. Effect of hepatic impairment on the pharmacokinetics of nirmatrelvir\/ritonavir, the first oral protease inhibitor for the treatment of COVID-19. J Clin Pharmacol. 2024;64(2):145\u201354.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1554_CR15","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/psp4.12980","volume":"12","author":"H Sato","year":"2023","unstructured":"Sato H, Marutani R, Takaoka R, et al. Model-based meta-analysis of ethnic differences and their variabilities in clearance of oral drugs classified by clearance mechanism. CPT Pharmacometr Syst Pharmacol. 2023;12(8):1132\u201342.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1554_CR16","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.2147\/DDDT.S479561","volume":"18","author":"R Zhang","year":"2024","unstructured":"Zhang R, Fan J, Han L, et al. Population pharmacokinetics and dosing regimen analysis of nirmatrelvir in Chinese patients with COVID-19 infection. Drug Des Devel Ther. 2024;18:5517\u201327.","journal-title":"Drug Des Devel Ther"},{"key":"1554_CR17","unstructured":"ClinicalTrials.gov. Study of PF-07321332 in Healthy Participants. https:\/\/clinicaltrials.gov\/study\/NCT04756531. Accessed 31 Mar 2025."},{"issue":"5","key":"1554_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1124\/dmd.121.000801","volume":"50","author":"H Eng","year":"2022","unstructured":"Eng H, Dantonio AL, Kadar EP, et al. Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-like protease, across animals and humans. Drug Metab Dispos. 2022;50(5):576\u201390.","journal-title":"Drug Metab Dispos"},{"key":"1554_CR19","unstructured":"KALETRA (lopinavir and ritonavir) [package insert]. Chicago, IL: AbbVie Inc.; 2023."},{"key":"1554_CR20","unstructured":"Ke Li Zhi (lopinavir\/ritonavir oral solution). https:\/\/drugs.dxy.cn\/pc\/drug\/P6xRbbOBv3IGWM5jjJeZiw==?ky=ritonavir. Accessed 20 Mar 2025."},{"issue":"9","key":"1554_CR21","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1093\/jac\/dku131","volume":"69","author":"M Arab-Alameddine","year":"2014","unstructured":"Arab-Alameddine M, Lubomirov R, Fayet-Mello A, et al. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. J Antimicrob Chemother. 2014;69(9):2489\u201398.","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01554-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:29:47Z","timestamp":1783160987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01554-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1554"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01554-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nanyang Li, Jicheng Yu, Jufang Wu, and Jing Zhang have no competing interests to declare. All other authors are employees of Pfizer and may hold stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See\n                      \n                      for more information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study design was reviewed and accepted by the Chinese Center for Drug Evaluation and an independent ethics committee before study initiation. This study was conducted in accordance with the Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines, guidelines for Good Clinical Practice, and applicable laws and regulations. Ethics committee meeting number is 2021M-023, and approval letter ID is (2021) Lin Shen No. (1013).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Nanyang Li: data curation, investigation, project administration, writing\u2014original draft, writing\u2014review and editing; Jicheng Yu: Data curation, investigation, project administration, writing\u2014original draft, writing\u2014review and editing; Jufang Wu: data curation, investigation, project administration, resources, supervision, writing\u2014original draft, writing\u2014review and editing; Jing Zhang: data curation, investigation, project administration, resources, supervision, writing\u2014original draft, writing\u2014review and editing; Ying Ma: conceptualization, data curation, formal analysis, methodology, validation, writing\u2014original draft, writing\u2014review and editing; Chunye Zhang: data curation, methodology, validation, writing\u2014original draft, writing\u2014review and editing; Xiaoran Han: conceptualization, data curation, formal analysis, methodology, validation, writing\u2014original draft, writing\u2014review and editing; Jackie Gerhart: conceptualization, data curation, methodology, resources, supervision, validation, writing\u2014original draft, writing\u2014review and editing; Shuangchen Cong: conceptualization, data curation, formal analysis, methodology, resources, supervision, validation, writing\u2014original draft, writing\u2014review and editing. Approval: all authors have read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}